Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
PluvictoⓇ grew to USD 256m; supply now unconstrained,
focusing on initiating new patients
Sales evolution
USD m, % cc
Ex-US
US
+217%
256
18
238
80
6
74
Q3 2022
Q3 2023
11 Investor Relations | Q3 2023 Results
GROWTH
P
PLUVICTO™
Continued progress in Q3
■ Growth rates slowed in the quarter given supply challenges earlier in the year
■ >200 active centers ordering in US and onboarding another approximately 130
■ Ex-US reimbursement discussions ongoing
Supply capacity now unconstrained; maintaining reliability
■ Millburn capacity expanded with FDA approval of two additional lines
Indianapolis site submitted for FDA approval
☐
NOVARTIS | Reimagining MedicineView entire presentation